NEW YORK, July 14 — A decades-old diabetes drug is now at the center of one of the most strategically significant aging research efforts in modern medicine. The TAME trial — Targeting Aging with Metformin — is testing whether a generic pill can delay the onset of multiple age-related diseases simultaneously, a shift in how medical science approaches the broader stakes of human longevity. Metformin received FDA approval for type 2 diabetes in 1994.
The TAME trial, led by Dr. Nir Barzilai at the Albert Einstein College of Medicine in New York, began enrolling participants in 2016. The study seeks to enroll 3,000 adults aged 65 to 79 who do not have diabetes but do have at least one age-related condition.
The trial is designed to test whether metformin can delay the onset of cardiovascular disease, cancer, dementia, and other age-related illnesses. The FDA approved the trial design in 2015, a landmark decision that recognized aging itself as a potential indication for clinical study. What this signals is a regulatory shift: the agency effectively acknowledged that delaying aging — not just treating individual diseases — could be a legitimate target for drug development.
Observational data has fueled the interest. A 2014 study published in Diabetes Care analyzed records from 180,000 patients and found that diabetics taking metformin had a 15% lower mortality risk compared to non-diabetics.
That finding, counterintuitive on its face, suggested the drug might confer benefits beyond glucose control. In the laboratory, the calculus is even more striking. A 2017 study in Aging Cell reported that metformin extended lifespan in C. elegans — a microscopic roundworm commonly used in aging research — by 20%.
Such results do not guarantee similar effects in humans, but they have helped build the scientific case for the TAME trial. The trial is expected to report results in 2025 to 2026. Funding comes from the American Federation for Aging Research, or AFAR, founded in 1981, and from private donors.
Strategically, the TAME trial represents a bet that intervening in the fundamental biology of aging could be more efficient than tackling each age-related disease individually. If metformin proves effective, the broader stakes involve not just extending lifespan but compressing the period of morbidity at the end of life.
What to watch next is the data. The trial’s outcome could reshape how regulators, researchers, and the pharmaceutical industry approach the aging process itself. For now, the field watches Barzilai’s team for results that could redefine the medical chessboard. Consult your doctor for medical advice.
Sources
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Metformin TAME Trial Tests Diabetes Drug for Anti-Aging Effects”, “description”: “NEW YORK, July 14 — A decades-old diabetes drug is now at the center of one of the most strategically significant aging research efforts in…”, “datePublished”: “2026-07-14T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Noah King”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}, “citation”: [{“@type”: “CreativeWork”, “url”: “https://en.wikipedia.org/wiki/Metformin”}]}
